Halozyme Therapeutics Inc
NASDAQ:HALO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.68
64.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Halozyme Therapeutics Inc
Halozyme Therapeutics Inc
Total Equity
Halozyme Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Total Equity
$452.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
27%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$18.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$7.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$15.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$29.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
|
Halozyme Therapeutics Inc
Glance View
Halozyme Therapeutics Inc. is a biopharmaceutical company that has carved out a niche in the increasingly competitive landscape of drug delivery and oncology solutions. Founded in 1998 and headquartered in San Diego, California, Halozyme focuses on enhancing the efficacy and convenience of therapeutic agents through its proprietary Enhanze™ drug delivery technology. This innovation allows for subcutaneous delivery of biologics, significantly improving patient experiences and treatment adherence compared to traditional intravenous methods. By partnering with major pharmaceutical companies, such as Roche and Bristol Myers Squibb, Halozyme has positioned itself as a key player in transforming the delivery of monoclonal antibodies, paving the way for more efficient and patient-friendly treatment protocols. As investors look towards the future, Halozyme’s robust pipeline of collaborations and products highlights its growth potential in the biotech sector. The company is not only expanding its own product offerings but also facilitating significant developments in the oncology space with partnerships that leverage its Enhanze technology. Key milestones, including product approvals and collaborations, have already begun to generate revenue, providing a solid foundation for future earnings. With a seasoned management team and a commitment to innovation, Halozyme stands out as a promising investment opportunity that aligns with trends favoring patient-centric healthcare solutions, while potentially offering significant returns for discerning investors intrigued by the biopharmaceutical landscape.
See Also
What is Halozyme Therapeutics Inc's Total Equity?
Total Equity
452.7m
USD
Based on the financial report for Sep 30, 2024, Halozyme Therapeutics Inc's Total Equity amounts to 452.7m USD.
What is Halozyme Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
27%
Over the last year, the Total Equity growth was 82%. The average annual Total Equity growth rates for Halozyme Therapeutics Inc have been 17% over the past three years , 13% over the past five years , and 27% over the past ten years .
You don't have any saved screeners yet
